Bill Wexler's Profits of DOOM Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bill Wexler's Profits of DOOM

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mesaone who wrote (2809)	9/16/1998 11:41:00 PM
From: BDR	Read Replies (1) of 4634

I visited your website and read the piece by Voelker. Evidently the future of Hextend is based on the following: <<< And Hextend's Phase 3 human clinical trials[2] showed a statistically important drop of 4 to 1 in coagulation related adverse events, when compared to generic hetastarch in normal saline.>>> Without knowing the denominator I can't comment on the clinical significance of this finding. However, as a surgeon, while volume expanders are useful, a company based on this product alone will not fulfill the promise of this statement: <<this company is gonna blow biotechs out of the water...soon enough>> You did, however, state that: <<Hextend is their their entry to being legit (fda approval) but... it is the other products which will really drive this company.>> I haven't thoroughly reviewed your site but I did not see a mention of the other products. May I ask what they are?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next